When Screening Guidelines Shift: Impacts on Healthcare Access & Use

Health Affairs
Health AffairsMay 8, 2026

Why It Matters

These guideline revisions drive larger preventive populations, altering utilization patterns and cost structures, while exposing capacity constraints that could undermine intended health benefits.

Key Takeaways

  • New ACC/AHA lipid guidelines lower treatment thresholds to 5‑10% risk
  • Prevent risk equations replace Pooled Cohort, improving risk calibration
  • Lp(a) testing recommended once to refine statin decisions in intermediate risk
  • Coronary calcium scoring offers medication‑free pathway for low‑risk patients
  • Expanding screening ages strains capacity, risking suboptimal care for high‑risk groups

Summary

The podcast examines how recent revisions to screening and treatment guidelines—particularly the ACC/AHA lipid recommendations, newer hypertension targets, and lowered colon‑cancer screening age—reshape health‑care utilization and spending.

The lipid update introduces the Prevent risk equations, lowers the treatment threshold to a 5‑10% 10‑year cardiovascular risk, and adds one‑time Lp(a) testing and coronary‑calcium scoring to guide statin use. These changes are deemed cost‑effective, comparable to many cancer‑screening tests, and aim to capture a larger low‑intermediate risk population. Hypertension guidance now pushes systolic/diastolic goals toward 120/80 for high‑risk patients, promising reductions in heart attacks, strokes, dementia, and kidney failure but also raising management complexity.

Pnon emphasizes that statins are inexpensive, safe, and have minimal downsides, noting a patient who only started therapy after an Lp(a) result. He also warns that expanding colon‑cancer screening to age 45 has already outpaced endoscopy capacity, potentially diverting resources from higher‑risk older adults.

For payers and providers, the shift means higher preventive service volumes, new diagnostic workflows, and the need for stronger primary‑care infrastructure. Without adequate implementation, expanded guidelines risk widening gaps in care and inflating costs rather than delivering the projected health gains.

Original Description

Health Affairs Publishing's Jeff Byers welcomes Duke University School of Medicine's Mike Pignone to the pod to explore the new cholesterol screening guidelines, how evolving screening and treatment guidelines (including colon cancer and breast cancer screening guidelines) influence care, and the broader cost implications for the health system.
Join Health Affairs Publishing on May 13 for an exclusive Insider virtual event exploring individual coverage health reimbursement arrangements ( https://www.healthaffairs.org/do/10.1377/he20260326.24181/full/?utm_medium=podcast&utm_source=this+week&utm_campaign=insidermarketing&utm_content=eventspecific ) (ICHRAs) with Urban Institute’s Jason Levitis.
Related Articles:
* Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol–Lowering Therapies Among Medicare Beneficiaries ( https://jamanetwork.com/journals/jamacardiology/fullarticle/2770174#google_vignette ) (JAMA)
* A cholesterol test you've never heard of is now recommended to prevent heart disease ( https://www.npr.org/2026/03/13/nx-s1-5747111/cholesterol-guidelines-lipoproteina-test ) (NPR)
* ACC/American Heart Association Issue Updated Guideline for Managing Lipids, Cholesterol ( https://newsroom.heart.org/news/accaha-issue-updated-guideline-for-managing-lipids-cholesterol ) (American Heart Association)
Sign up for Health Affairs' free newsletter ( https://share.hsforms.com/26dGfZSq8SjaPUznLYa3kfQnnawj ) to catch up on our new articles, podcasts, and events.
Health Affairs This Week
Episode 247
May 8, 2026
★ Additional episodes: http://www.healthaffairs.org

Comments

Want to join the conversation?

Loading comments...